GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arctic Bioscience AS (OSL:ABS) » Definitions » EBITDA Margin %

Arctic Bioscience AS (OSL:ABS) EBITDA Margin % : -146.42% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Arctic Bioscience AS EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Arctic Bioscience AS's EBITDA for the six months ended in Dec. 2023 was kr-21.48 Mil. Arctic Bioscience AS's Revenue for the six months ended in Dec. 2023 was kr14.67 Mil. Therefore, Arctic Bioscience AS's EBITDA margin for the quarter that ended in Dec. 2023 was -146.42%.


Arctic Bioscience AS EBITDA Margin % Historical Data

The historical data trend for Arctic Bioscience AS's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arctic Bioscience AS EBITDA Margin % Chart

Arctic Bioscience AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial -8.13 -101.91 -184.62 -88.39 -115.97

Arctic Bioscience AS Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only -207.20 -89.04 -87.92 -92.55 -146.42

Competitive Comparison of Arctic Bioscience AS's EBITDA Margin %

For the Biotechnology subindustry, Arctic Bioscience AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arctic Bioscience AS's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arctic Bioscience AS's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Arctic Bioscience AS's EBITDA Margin % falls into.



Arctic Bioscience AS EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Arctic Bioscience AS's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-39.14/33.75
=-115.97 %

Arctic Bioscience AS's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-21.479/14.669
=-146.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arctic Bioscience AS  (OSL:ABS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Arctic Bioscience AS EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Arctic Bioscience AS's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Arctic Bioscience AS (OSL:ABS) Business Description

Traded in Other Exchanges
N/A
Address
Industrivegen 42, Orsta, NOR, 6155
Arctic Bioscience AS is a Norwegian biotechnology company. The company is focused on developing products and solutions based on bioactive marine compounds. The product portfolio includes nutraceuticals and pharmaceuticals. It is currently developing a novel, cost-efficient oral treatment (HRO350) for mild-to-moderate psoriasis. Its nutraceutical products are sold globally to both B2C and B2B under the Romega brand.

Arctic Bioscience AS (OSL:ABS) Headlines

No Headlines